For individuals with type 1 diabetes, intraindividual body weight variability, or body weight cycling, is associated with an increased risk for renal events.

Investigators compared the outcomes of patients with type 2 diabetes who continued versus stopped metformin after progressing to stage 4 chronic kidney disease.

• Glucagon-like peptide 1 receptor agonists (GLP-1) (medicines used to lower blood glucose) probably reduce the risk of death due to any cause but may have little or no death due to a heart attack in ...

INNOVATE Corp. surged 150% after its subsidiary MediBeacon received FDA approval for its TGFR system. See why I rate VATE ...

Body weight cycling in type 1 diabetes is associated with increased risk of chronic kidney disease. Maintaining stable weight ...

The dual SGLT1/2 inhibitor sotagliflozin (Inpefa) reduced the risk for myocardial infarction (MI) and stroke in high-risk ...

Observational data fill a knowledge gap in the absence of randomized trials comparing empagliflozin vs dapagliflozin in patients with type 2 diabetes.

In a remarkable display of market confidence, VATE stock has surged to a 52-week high, with shares trading at an impressive $13.31, representing a dramatic 309% increase from its 52-week low of $3.25.

Travere’s stock price climbed by 14% following the announcement that it will seek an FDA label expansion for Filspari.

Elevated serum fibroblast growth factor 23 levels at baseline are linked to a 29% increased risk for diabetic kidney disease, ...

The Type C meeting follows the recent public workshop led by the PARASOL (Proteinuria and GFR as Clinical Trial ... normal filtration mechanism in the kidney. Once in the urine, protein is considered ...

Company completed Type C meeting with FDA, aligning on its plan to submit an sNDA; submission expected around end of 1Q25If approved, FILSPARI ...